Iryna Drozd
Adicet Bio (NASDAQ:ACET) stock jumped 10% Monday morning after the company said it had received FDA fast track designation for its CAR-T cell therapy candidate ADI-270 for the treatment of metastatic/advanced clear cell renal cell carcinoma, a type of kidney cancer.
The designation was granted for the treatment of patients with the disease who have been treated with an immune checkpoint inhibitor and a vascular endothelial growth factor inhibitor.
The FDA cleared the company in June to begin Phase 1 testing of ADI-270 for renal cell carcinoma.